This Rail Is Back on Track, So Board on Pullbacks

Coal cooled and a one-time write-down made the headline look rough, but the railroad ran smoother underneath. Faster trains, less yard time, and better on-time deliveries say the engine’s fine. If sellers dump the news, nibble on red, add on calm pullbacks, and keep a tight stop.

In July, crypto history was made.

Congress passed the first federal framework for digital assets—and almost overnight, the market surged past $4 trillion.

Here’s why:

✓ Banks now have the green light to offer crypto services.
✓ Wall Street institutions can finally scale in.
✓ The uncertainty holding crypto back is gone.

This is the moment early movers have been waiting for.

Our Crypto Revolution report shows you exactly how to prepare—and it’s 100% free.

You’ll also get $788 in bonus resources when you claim your copy.

The floodgates are open.

Don’t wait until the crowd catches on.

[Claim Your Free Copy Today]

© 2025 Boardwalk Flock LLC. All Rights Reserved. 2382 Camino Vida Roble, Suite I Carlsbad, CA 92011, United States
*The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Readers acknowledge that the authors are not engaging in the rendering of legal, financial, medical, or professional advice. The reader agrees that under no circumstances Boardwalk Flock, LLC is responsible for any losses, direct or indirect, which are incurred as a result of the use of the information contained within this, including, but not limited to, errors, omissions, or inaccuracies.
Results may not be typical and may vary from person to person. Making money trading digital currencies takes time and hard work. There are inherent risks involved with investing, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk.

Markets woke up wobbly again, but the slide’s eased as bank nerves cool a touch. Early panic rotated into okay, maybe not a crisis after a better print from one of the regionals, so it’s less full-on risk-off and more cautious shuffle.

The bigger picture is that earnings are doing damage control while trade drama and a government shutdown keep tossing banana peels on the floor. Expect choppy tape as buyers nibble dips, sellers fade pops, and momentum takes the day off.

Elite Trade Club now offers text alerts — so you get trending stocks and market-moving news sent straight to your phone before the bell.

Email’s great. Texts are faster.

👉 Click here to get our pre-market report to your cell for free!

You’ll be first in line when the market starts moving.

Premarket Earnings:

Economic Reports:

*Data subject to delay if government shutdown continues

Revolution Medicines (NASDAQ: RVMD) popped after the FDA handed daraxonrasib a National Priority Voucher, which is basically saying we care about this, and the agency wants to move faster.

Cool! Just know it’s non-transferable (so, no quick cash grab), and the real game is still those two Phase 3 trials for tough cancers. Timelines haven’t changed as the first big readout isn’t expected until 2026. That means today is a sugar high, tomorrow is a calendar grind.

RAS is one of cancer’s nastiest locks, and RVMD thinks it’s got a better key. If endpoints hit, this could be a franchise, not a fling. But between now and then? Trial execution, safety, and the never-ending question of how much cash is in the tank.

Know that vouchers don’t cure patients, data does. The stock can trade like a rodeo around conference abstracts, whispers, and financing rumors. Dilution is still very possible if they want to keep sprinting through 2026.

My Take For You: If you’re in from lower, trim a little into strength and keep a runner for catalysts. If you’re flat, let it breathe, and build a starter only if you’re comfortable living with binary outcomes.

My Verdict: Catalyst vehicle. Accumulate on red days, sell rips, and keep your stops honest until the Phase 3s do the talking.

GRAIL (NASDAQ: GRAL) jumped after Samsung agreed to invest and help distribute the Galleri multi-cancer early detection test in Asia.

That’s real stuff, as capital to extend the runway and a heavyweight channel in South Korea, with potential expansion to Japan and Singapore. Early detection is the dream, reimbursement is the rent, and GRAIL still needs payers to nod, at home and abroad.

This is a blue-chip partner that shrinks go-to-market headaches and hints at mainstream adoption. If regulators and insurers play ball, revenue can scale faster than a sales team alone ever would. But medical tests live and die on sensitivity, specificity, and clinical utility.

There are still some issues. Equity cash helps, but still a build-it-while-proving-it story. Regulators and health systems move on their own calendars. False positives and follow-up costs can spook policymakers.

My Take For You: If you bought the rumor, harvest some into this spike and ride a slice. If you’re new, don’t chase it; instead, hunt dips or a calm consolidation while you track reimbursement wins.

My Verdict: Promising platform, partner de-risking helps. Buy on pullbacks if you’re patient and size it like a med-tech. Know that proof and payer coverage are the real catalysts.

The market rewards those who act early.

That’s why our team has just released an all-new report—5 Stocks Set to Double.

These picks were chosen because they stand out with:

In the past, this exact type of report has uncovered stocks that posted triple digit runs of +175%, +498%, even +673%.

The new report is free—but only until midnight tonight.

Download your free copy here before time runs out

Don’t just settle for growth. Aim for massive.

CSX (NASDAQ: CSX) reported a muddy quarter on paper, coal revenue slid and a goodwill writedown dinged the optics, but under the hood the railroad ran tighter. Faster trains, less terminal dwell, better on-time performance.

Intermodal picked up, big construction chokepoints cleared, and management sounded confident they can win more freight as industrial projects along the network ramp.

This was an interesting quarter, because rails are operating-leverage machines. When service improves, pricing and volumes tend to follow, and margins can expand quietly for several quarters. The bad is that coal’s a shrinking friend, and macro wobbles (rates, trade rules, trucking capacity) can whipsaw volumes.

Remember that one-time charges are… one-time, but mix matters. If export coal stays weak and merchandise lags, the math gets tougher. Keep an eye on operating ratio trend and intermodal trip-plan compliance, as that’s the heartbeat.

My Take For You: If you’re long, stay seated and trail a stop under recent support. Eyeing an entry? Don’t pay up on a relief pop, wait for a pullback toward the 50-day or a tidy base, then scale in.

My Verdict: Quality operator tightening the screws. Accumulate on weakness for patient holders, this is a compounding story if service gains stick and the economy stays out of the ditch.

We’re seeing some rocket fuel on this tremor-fighter after late-stage results came in strong. Price targets are getting air-mailed to the stratosphere, and traders are acting like launch day never ends. Heads up, though, the company also tapped the cash register with a big share sale, smart for launch prep, but it fattens the share count and can cool the party.

It’s the classic biotech two-step. Great data, then raise money, then the waiting room. Approval odds look better, but timelines still stretch, and label or safety quirks can show up late.

A clean, no-drama print. Revenue right on the nose, adjusted profits up, and deal-making fees doing the heavy lifting. That’s enough to get regional-bank skeptics peeking back over the fence. The questions now are the usual suspects of deposit costs, credit losses, and what management says about the rest of the year.

This feels more like a steady fundamentals drift than a meme moment. Banks can grind higher on guidance and buybacks, but one messy credit headline and the crowd ghosts fast.

The miner-turned-AI-datacenter play priced a jumbo debt deal to supercharge build-out, which is great for capacity, and spicy for leverage. At the same time, crypto’s wobbling, which tends to yank the steering wheel on anything tied to mining or power-hungry compute.

Big plans plus big borrowing can work, but it raises the bar on execution and interest costs. If the Bitcoin tide slips, even the best site plans look less shiny.

No hype. No jargon.

Just the 7 stocks showing the most powerful setups for the next 30 days.

This new free report breaks it all down — and it could help you spot your next short-term winner.

These are the companies most likely to shine while others are left chasing yesterday’s news.

Download your copy here before your next trade.

That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.

Best Regards,

— Adam Garcia
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.